ADC Therapeutics SA Revenue 2019-2022 | ADCT

ADC Therapeutics SA revenue from 2019 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
ADC Therapeutics SA Annual Revenue
(Millions of US $)
2021 $34
2020 $
2019 $2
2018 $1
ADC Therapeutics SA Quarterly Revenue
(Millions of US $)
2022-06-30 $17
2022-03-31 $46
2021-12-31 $17
2021-09-30 $13
2021-06-30 $4
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30 $2
2018-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.402B $0.034B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $152.052B 9.22
GSK (GSK) United Kingdom $62.454B 7.50
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
QIAGEN (QGEN) Netherlands $9.939B 16.64
Ginkgo Bioworks Holdings (DNA) United States $6.283B 0.00
Myovant Sciences (MYOV) United Kingdom $2.444B 0.00
Arcus Biosciences (RCUS) United States $1.941B 37.89
Emergent Biosolutions (EBS) United States $1.068B 6.19
Zymeworks (ZYME) Canada $0.354B 0.00
Enzo Biochem (ENZ) United States $0.113B 0.00
Gelesis Holdings (GLS) United States $0.083B 0.00
SQZ Biotechnologies (SQZ) United States $0.073B 0.00
Ambrx Biopharma (AMAM) United States $0.042B 0.00
Biohaven Pharmaceutical Holding (BHVN) United States $0.000B 0.00